BIOTECHNOLOGY IP
biotechnology centre in the north-western region, while there have been important successes in pharmaceuticals in the central and northern regions.
B
Mexico has the necessary natural resources to generate and export biological technology. However, in the absence of suitable regulation, there was a risk of overexploitation of its rich biodiversity and, in order to face this issue, the Law on Biosafety of Genetically Modifi ed Organisms, better known as the Monsanto Law, was passed.
T e objective of this law was to “regulate the
confi ned utilisation activities, experimental liberation, pilot scheme liberation, commercial liberation, trading, import and export of genetically modifi ed organisms (GMOs) so as to prevent, avoid or reduce the possible harm that these activities could cause to human health or to the environment or the biological diversity or animal, vegetable and marine health” (Article 1). T is means that special care has to be taken in the regulation of genetic materials so as to avoid contravening the object of the law, including the protection of the inventors of these products through the Industrial Property Law and the Federal Law on Vegetable Varieties.
On the other hand, Article 6, paragraph VII of this law states that excluded from the scope of application of this law, are “… IP on biotechnological products or processes subject to the Industrial Property Law, the Federal Law on Vegetable Varieties and the international agreements of which the Mexican United States are part.”
It is important to underline that this exclusion from these laws or agreements is purely about their scope, and is not intended to create exclusions since, as has already has been established, genetic inventions or creations, either of animal or vegetable origin, are respectively regulated by the Industrial Property Law and the Federal Law on Vegetable Varieties.
The mora l clause Mexican legislative practice includes a ‘moral clause’, which ensures that no patent, registration or authorisation is to be granted, nor can be published in the Gazette, to any fi gure or institution regulated by this law, when the content or form thereof is contrary to public order, morals and good manners or is against any legal provision. T is moral clause was designed “to protect public order and morals, including the protection of human, animal and vegetable life and health, and to avoid serious damage to nature or the environment”.
It is apparent that these concepts are abstract and depend on special temporary social factors and
www.worldipreview.com
iotechnology is presently one of the fastest developing sciences in Mexico. For instance, there is an excellent marine
on development itself which, arguably, is being generated within biotechnology. T ere is strong pressure within society for greater care to be taken and for limits to put on some scientifi c investigations.
It is important to point out that Mexico is one of the ten world leaders in the sowing of GM crops. Nevertheless, at present, only transgenic soya and cotton are being sown commercially; although the possibility of doing the same with other species of transgenic plants is being researched.
On the other side, biotechnological research in Mexico faces a serious problem because of the lack of impetus and this means that researchers, very oſt en, decide to migrate abroad.
T e Mexican Academy of Sciences and the Yucatan Centre for Scientifi c Research (CICY) have acquired a positive international reputation, but researchers consider that Mexico still has a great deal to do to connect their achievements to national industry, as the brain drain and a technological defi cit become more and more acute.
Dr. Victor M. Loyola-Vargas, a member of the Academy, considers that: “As the research centres and the universities are treated as entities, they have no places available and, therefore, there are no jobs for postgraduates. How can we generate our own technology if we are not generating new knowledge?”
Dr. Lourival D. Possani, a researcher at the Biotechnology Institute of the National Autonomous University of Mexico (UNAM) adds: “A number of centres are involved in biotechnology but no new places have been created, or these are limited to state universities or National Science and Technology Council centres, and these are not generally the best places for the production of inputs with important aggregated value capable of producing products for public consumption.”
Herein lies Mexico’s true challenge: how to
develop biotechnology, by means of IP, through patent protection.
Notwithstanding the existence of a great body of scientifi c research, as can be seen from the activities of
the research centres, there is no culture of protection for these processes through patents.
Biotechnology, as a constituent part of biology, and its activities per se, imply creativity through biotechnology capable of generating new processes that have industrial applications and, because they stem from inventive activity, should clearly be protected, as are other inventions, by the Industrial Property Law, through patents.
Biotechnology depends on biodiversity for its future development so it has the tools necessary for its
Gabriela Fernández has eight years experience in IP law. She holds a law degree from La Salle University and specialised in IP law at the Universidad Panamericana. She is an active member of the International Trademark Association (INTA) and the Interamerican Association of Intellectual Property (ASIPI), and speaks Spanish, English and basic Mandarin.
World Intellectual Property Review Annual 2014 85
“BIOTECHNOLOGICAL RESEARCH IN MEXICO FACES A SERIOUS PROBLEM BECAUSE OF THE LACK OF IMPETUS AND THIS MEANS
THAT RESEARCHERS, VERY OFTEN, DECIDE TO MIGRATE ABROAD.”
conservation and utilisation. IP protection will promote the growth of this technology.
In developing countries a link between IP rights and genetic resources has become essential before the patentability of living matter can be broadened; the legislature must modify the Mexican Industrial Property Law so as to include measures for regulating
patents so that the law in Mexico is in accord with the legislation in other countries that have already legislated positively in this matter.
Gabriela Fernández is a director at Fernandez Manzo Y Asociados. She can be contacted at:
gabyf@fernandezmanzo.com.mx
the registration of biotechnological
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172